Attached files

file filename
EX-10.25 - EX-10.25 - vTv Therapeutics Inc.vtvt-ex1025_142.htm
10-K - 10-K - vTv Therapeutics Inc.vtvt-10k_20191231.htm
EX-32.1 - EX-32.1 - vTv Therapeutics Inc.vtvt-ex321_6.htm
EX-31.2 - EX-31.2 - vTv Therapeutics Inc.vtvt-ex312_9.htm
EX-31.1 - EX-31.1 - vTv Therapeutics Inc.vtvt-ex311_13.htm
EX-23.1 - EX-23.1 - vTv Therapeutics Inc.vtvt-ex231_10.htm
EX-21.1 - EX-21.1 - vTv Therapeutics Inc.vtvt-ex211_8.htm
EX-10.26 - EX-10.26 - vTv Therapeutics Inc.vtvt-ex1026_143.htm
EX-4.3 - EX-4.3 - vTv Therapeutics Inc.vtvt-ex43_144.htm

 

EXHIBIT 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of vTv Therapeutics Inc. (the “Company”) on Form 10-K for the period ended December 31, 2019 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Rudy C. Howard, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, in my capacity as an officer of the Company that, to my knowledge:

 

1.

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

2.

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: February 20, 2020

 

By:

/s/ Rudy C. Howard

 

Rudy C. Howard

 

Chief Financial Officer